Orchid Pharma Ltd (ORCHPHARMA)
₹1369.8
🔔 Earnings Growth Alert
Orchid Pharma reports 73.6% YoY earnings growth, anticipates future earnings growth at 42.44% annually
Analyst Rating
based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Orchid Pharma Ltd. An average target of ₹1252.33
Source: S&P Global Market Intelligence
Orchid Pharma Ltd Share analysis
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,351.15₹1,416.9552 Week's Low
52 Week's High
₹432.05₹1,425
| Returns % | |
| 1 Month Return | + 19.91 % |
| 3 Month Return | + 29.19 % |
| 1 Year Return | + 145.04 % |
| Market Stats | |
| Previous Close | ₹1,375.90 |
| Open | ₹1,360.05 |
| Volume | 90.69K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹6,978.44Cr |
Key Statistics
| P/E Ratio | 71.89 |
| PEG Ratio | 9.23 |
| Market Cap | ₹6,978.44 Cr |
| P/B Ratio | 2.37 |
| EPS | 7.8 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹6,978.44 Cr | 5029.17% | 0.66 | ₹48 Cr | ₹665 Cr |
 | NA | ₹2,794.56 Cr | 47.29% | 0.53 | ₹38 Cr | ₹1,417 Cr |
 | NA | ₹3,315.04 Cr | 1.4% | 0.74 | ₹67 Cr | ₹926 Cr |
| BUY | ₹17,994.51 Cr | 16.49% | 0.50 | ₹308 Cr | ₹1,016 Cr |
| NA | ₹49.49 Cr | -12.65% | 0.72 | ₹2 Cr | ₹68 Cr |
Company Information
Share Price: ₹1369.80 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹6,978.44Cr as of today
Revenue: ₹217.10Cr as on March 2024 (Q1 24)
Net Profit: ₹33.50Cr as on March 2024 (Q1 24)
Listing date: 12 May, 1995
Chairperson Name: Ram Gopal Agarwal
| Organisation | Orchid Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
What's happening today
Today's Timeline - Invalid Date
06:45 AM
-Orchid Pharma reports 73.6% YoY earnings growth and anticipates future earnings growth at an impressive rate of 42.44% annually.
Key events for Orchid Pharma Ltd
Orchid Pharma Reports Strong Earnings Growth - 24 Jul, 2024
Orchid Pharma, a lesser-known yet promising player in India's pharmaceutical sector, has shown notable achievements with robust growth prospects. The company reported a substantial earnings increase of 73.6% over the past year and anticipates future earnings growth at an impressive rate of 42.44% annually.
Orchid Pharma Partners with Cipla for Antibiotic Launch - 01 Jul, 2024
Orchid Pharma has partnered with Cipla to introduce the new antibiotic, Cefepime-Enmetazobactam, in India. The drug is approved for treating complicated urinary tract infections, hospital-acquired pneumonia, and ventilator-associated pneumonia. Orchid Pharma's shares rose by 4.2% following the announcement of the partnership.
Orchid Pharma Partners with Cipla to Launch Antibiotic in India - 30 Jun, 2024
Orchid Pharma has partnered with Cipla to launch the antibiotic Cefepime-Enmetazobactam in India for complicated urinary tract infections, hospital-acquired pneumonia, and ventilator-associated pneumonia indications. The partnership aims to ensure widespread and rapid distribution of this antibiotic combination across India.
Orchid Pharma Partners with Cipla for Distribution of New Drug - 29 Jun, 2024
Orchid Pharma has partnered with Cipla to distribute its new drug, Cefepime-Enmetazobactam, across India in the fight against AMR. This marks a significant milestone for India's pharmaceutical industry.
Orchid Pharma Partners with Cipla to Launch New Drug - 28 Jun, 2024
Orchid Pharma has partnered with Cipla to launch a new antibiotic combination drug, Cefepime-Enmetazobactam, for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) indications. However, Orchid Chemicals and Pharmaceuticals have been referred to the corporate debt restructuring cell of RBI due to liquidity constraints.
Insights on Orchid Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 4 quarters, 184.81 Cr → 230.46 Cr (in ₹), with an average increase of 7.0% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 9.4 Cr → 32.96 Cr (in ₹), with an average increase of 32.0% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 10.40% to 15.18% in Mar 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, ORCHPHARMA stock has moved up by 18.2%
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ORCHPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, ORCHPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 69.84% of holdings in Mar 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 11.53% to 10.47% in Mar 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 4.14% to 1.96% in Mar 2024 quarter
Company Financials
| Q'1 24 | Q/Q Change | |
|---|---|---|
Revenue | ₹217.10Cr | ↓1.58% |
Net Income | ₹33.50Cr | ↑10.96% |
Net Profit Margin | 15.43% | ↑12.71% |
| 2023 | Y/Y Change | |
|---|---|---|
Revenue | ₹665.90Cr | ↑19.00% |
Net Income | ₹48.47Cr | ↑2,987.26% |
Net Profit Margin | 7.28% | ↑2,500.00% |
| 2023 | Y/Y Change | |
|---|---|---|
Total Assets | ₹1,309.37Cr | ↑11.24% |
Total Liabilities | ₹577.40Cr | ↑15.70% |
| 2023 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | ₹13.39Cr | ↓85.05% |
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 69.84% | 0.00 | |
| Foreign Institutions | 1.96% | 0.00 | |
| Mutual Funds | 15.18% | 0.00 | |
| Retail Investors | 10.47% | 0.00 | |
| Others | 2.56% | 0.00 |
Key Indicators
Orchid Pharma Ltd Valuation
Orchid Pharma Ltd in the last 5 years
Lowest (-871.56x)
April 8, 2022
Industry (56.07x)
July 23, 2024
Today (71.89x)
July 23, 2024
Highest (105.04x)
September 14, 2022
Earnings and Dividends
Orchid Pharma Ltd Earnings Results
Orchid Pharma Ltd’s net profit fell -44.27% since last year same period to ₹32.96Cr in the Q4 2023-2024. On a quarterly growth basis, Orchid Pharma Ltd has generated 11.99% jump in its net profits since last 3-months.
Read More about Earnings ResultsOrchid Pharma Ltd Dividends May,2012
In the quarter ending March 2012, Orchid Pharma Ltd has declared dividend of ₹3 - translating a dividend yield of 0.44%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Orchid Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Orchid Pharma Ltd shares.
Orchid Pharma Ltd (ORCHPHARMA) share price today is ₹1369.8
Orchid Pharma Ltd is listed on NSE
Orchid Pharma Ltd is listed on BSE
- Today’s highest price of Orchid Pharma Ltd is ₹1416.95.
- Today’s lowest price of Orchid Pharma Ltd is ₹1351.15.
PE Ratio of Orchid Pharma Ltd is 71.89
PE ratio = Orchid Pharma Ltd Market price per share / Orchid Pharma Ltd Earnings per share
Today’s traded volume of Orchid Pharma Ltd(ORCHPHARMA) is 90.69K.
Today’s market capitalisation of Orchid Pharma Ltd(ORCHPHARMA) is ₹6978.44Cr.
| Orchid Pharma Ltd(ORCHPHARMA | Price |
|---|---|
52 Week High | ₹1425 |
52 Week Low | ₹432.05 |
Orchid Pharma Ltd(ORCHPHARMA) share price is ₹1369.8. It is down -3.87% from its 52 Week High price of ₹1425
Orchid Pharma Ltd(ORCHPHARMA) share price is ₹1369.8. It is up 217.05% from its 52 Week Low price of ₹432.05
| Orchid Pharma Ltd(ORCHPHARMA | Returns |
|---|---|
1 Day Returns | -6.1% |
1 Month Returns | 19.91% |
3 Month Returns | 29.19% |
1 Year Returns | 145.04% |